Pre-Clinical Research or Clinical Trials for "stargardt"
as of 10/11/2020 - list below was compiled from clinicaltrials.gov (search for 'stargardt') plus some pre-clinical links.
(contact me on twitter: @stargardtp)| Active | Source | Intervention Name | Intervention Type | Study Type | Conditions | Pre-Clinical or Trial Info | Phase | Status | LastUpdate | Brief Title | Publications |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Iveric Bio | ABCA4 MiniGene | Drug | Intervention | Stargardt Disease |
Pre-Clinical Link | Pre-Clinical, not recruiting |
10/11/2020 | ABCA4 MiniGene Gene Therapy - Pre-Clinical Pipeline | |||
| AGTC | dual AAV ABCA4 Gene Therapy | Drug | Gene Therapy | Stargardt Disease |
Pre-Clinical Link | Pre-Clinical, not recruiting |
11/5/2019 | dual AAV - Pre-Clinical Pipeline | |||
| University of Wisconsin | Gene Augmentation | Drug | Gene Therapy | Stargardt Disease, others |
Pre-Clinical Link | Pre-Clinical, not recruiting |
11/5/2019 | Gene Augmentation - Pre-Clinical Pipeline | |||
| University of California, Berkeley | Optogenetics | Drug | Genetics | Stargardt Disease, others |
Pre-Clinical Link | Pre-Clinical, not recruiting |
3/15/2019 | Optogenetics - Pre-Clinical Pipeline | |||
| Radboud University | AONs | Drug | Intervention | Stargardt Disease, others |
Pre-Clinical Link | Pre-Clinical, not recruiting |
1/1/2019 | Antisense Oglionucleotides (AONs) - Pre-Clinical Pipeline | Genet Med-2019, Genes (Basel)-2019 | ||
| Stargazer Pharmaceuticals, Inc. | STG-001 | Drug | Interventional | Stargardt Disease-1 |
NCT04489511 | Phase 2 | Not yet recruiting |
7/28/2020 | Study of STG-001 in Subjects With Stargardt Disease | ||
| National Institutes of Health Clinical Center (CC) | Metformin hydrochloride | Drug | Interventional | ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration |
NCT04545736 | Phase 1/Phase 2 | Not yet recruiting |
10/8/2020 | Oral Metformin for Treatment of ABCA4 Retinopathy | ||
| IVERIC bio, Inc. | Zimura | Drug | Interventional | Stargardt Disease 1 |
NCT03364153 | Phase 2 | Recruiting |
9/30/2020 | Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) | ||
| Alkeus Pharmaceuticals, Inc. | ALK-001 | Drug | Interventional | Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related) |
NCT02402660 | Phase 2 | Recruiting |
5/1/2020 | Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease | J Biol Chem-2011, J Biol Chem-2011, Mol Vis-2013, Proc Natl Acad Sci U S A-2015, Adv Exp Med Biol-2016 | |
| Drug | Interventional | Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related) |
NCT04239625 | Phase 2 | Enrolling by invitation |
1/22/2020 | Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) | J Biol Chem-2011, J Biol Chem-2011, Mol Vis-2013, Proc Natl Acad Sci U S A-2015, Adv Exp Med Biol-2016 | |||
| Drug | Interventional | Stargardt Disease, Age-related Macular Degeneration, Other Retinal Dystrophies |
NCT02230228 | Phase 1 | Completed |
3/21/2015 | Phase 1 Safety Study of ALK-001 in Healthy Volunteers | ||||
| National Institutes of Health Clinical Center (CC) | Medmont Darl Adapted Chromatic (DAC) | Device | Interventional | Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease |
NCT02617966 | N/A | Recruiting |
10/1/2020 | Rod and Cone Mediated Function in Retinal Disease | Ageing Res Rev-2002, Invest Ophthalmol Vis Sci-1979, Invest Ophthalmol Vis Sci-2011 | |
| Johns Hopkins University | Anterior Chamber (AC) Tap | Other | Observational | Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related) |
NCT02875704 | Recruiting |
9/1/2020 | Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy | |||
| Queen's University, Belfast | Virtual Reality Headset based tests | Device | Observational | Low Vision, Retinitis Pigmentosa, Stargardt Disease 1, Stargardt Disease 3, Stargardt Disease 4, Albinism |
NCT04281732 | Recruiting |
2/21/2020 | Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision | |||
| Foundation Fighting Blindness | Observational [Patient Registry] | Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome |
NCT02435940 | Recruiting |
12/12/2018 | Inherited Retinal Degenerative Disease Registry | |||||
| Kubota Vision Inc. | Emixustat | Drug | Interventional | Stargardt Disease |
NCT03772665 | Phase 3 | Active, not recruiting |
8/27/2020 | Safety and Efficacy of Emixustat in Stargardt Disease | ||
| Drug | Interventional | Stargardt Disease, Macular Atrophy |
NCT03033108 | Phase 2 | Completed |
1/10/2019 | Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease | ||||
| Ophthalmos Research and Education Institute | Madeos | Dietary Supplement | Interventional | Dry AMD, Stargardt Disease 1 |
NCT03297515 | N/A | Active, not recruiting |
3/27/2020 | Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease | ||
| National Institutes of Health Clinical Center (CC) | Observational | Retinal Degeneration, ABCA4-Related Retinopathies |
NCT01736293 | Active, not recruiting |
9/25/2020 | Natural History of Eye Diseases Related to ABCA4 Mutations | Nat Genet-1997, Invest Ophthalmol Vis Sci-2009, Nat Rev Genet-2011 | ||||
| Sanofi | Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Drug | Interventional | Stargardt's Disease |
NCT01736592 | Phase 1/Phase 2 | Active, not recruiting |
8/10/2020 | Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration | ||
| Federal University of São Paulo | injection of hESC-RPE in suspension | Procedure | Interventional | Age Related Macular Degeneration, Stargardt's Disease, Exudative Age-related Macular Degeneration |
NCT02903576 | Phase 1/Phase 2 | Completed |
7/20/2020 | Stem Cell Therapy for Outer Retinal Degenerations | ||
| Astellas Pharma Inc | MA09-hRPE | Biological | Interventional | Stargardt's Macular Dystrophy |
NCT01345006 | Phase 1/Phase 2 | Completed |
2/20/2017 | Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy | ||
| Biological | Interventional | Stargardt's Macular Dystrophy |
NCT01469832 | Phase 1/Phase 2 | Completed |
2/20/2017 | Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Lancet-2012, Lancet-2015 | |||
| Biological | Observational | Stargardt's Macular Dystrophy |
NCT02445612 | Completed |
11/25/2019 | Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients | |||||
| Biological | Observational | Stargardt's Macular Dystrophy |
NCT02941991 | Completed |
10/30/2019 | A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | |||||
| Southwest Hospital, China | Subretinal transplantation | Procedure | Interventional | Macular Degeneration, Stargardt's Macular Dystrophy |
NCT02749734 | Phase 1/Phase 2 | Unknown status |
1/29/2018 | Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases | ||
| Catholic University of the Sacred Heart | Saffron supplementation | Dietary Supplement | Interventional | Retinal Degeneration, Genetic Disease, Single-Gene Defects, Macular Dystrophy |
NCT01278277 | Phase 1/Phase 2 | Unknown status |
7/18/2017 | Saffron Supplementation in Stargardt's Disease | Invest Ophthalmol Vis Sci-2010 | |
| University of Utah | 4-Methylpyrazole | Drug | Interventional | Macular Dystrophy, Corneal |
NCT00346853 | Phase 1 | Completed |
8/3/2020 | Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy | ||
| National Institutes of Health Clinical Center (CC) | Docosahexaenoic Acid (DHA) Dietary Supplement | Drug | Interventional | Macular Degeneration |
NCT00060749 | Phase 1 | Completed |
6/30/2017 | Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy | Nat Genet-2001 | |
| CHABiotech CO., Ltd | MA09-hRPE | Biological | Interventional | Stargardt's Macular Dystrophy |
NCT01625559 | Phase 1 | Unknown status |
2/16/2015 | Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) | ||
| Escuela Neijing | Acupuncture and massage | Other | Interventional | Age-related Macular Degeneration, Stargardt Disease, Macular Dystrophy |
NCT02255981 | N/A | Completed |
6/11/2020 | Efficacy of Acupuncture in Macular Diseases | Results | |
| University of Utah | Over the counter DHA/EPA dietary supplementation | Dietary Supplement | Interventional | Dominantly Inherited Stargardt's Disease (STGD3) |
NCT00420602 | N/A | Completed |
5/8/2018 | DHA Supplementation in Patients With STGD3 | ||
| University of Pennsylvania | Retinal imaging | Procedure | Observational | Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy |
NCT01866371 | Suspended |
3/24/2020 | High Resolution Retinal Imaging | |||
| Foundation Fighting Blindness | Observational | Stargardt Disease |
NCT01977846 | Completed |
10/30/2019 | A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies | Ophthalmol Retina-2017, Ophthalmol Retina-2017, JAMA Ophthalmol-2017, JAMA Ophthalmol-2017, Results | ||||
| Johns Hopkins University | Observational | Stargardt Disease |
NCT02410122 | Completed |
8/1/2018 | The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy | |||||
| Medical University of Vienna | functional magnetic resonance imaging (fMRI) | Diagnostic Test | Observational | Macula; Degeneration, Congenital or Hereditary, Retina Disorder |
NCT03517241 | Unknown status |
5/3/2018 | Objective Assessment of Macular Function at Retinal and Cortical Levels | |||
| Retina Institute of Hawaii | Observational | Retinal Diseases, Stargardt's Disease, Retinitis Pigmentosa |
NCT01790958 | Completed |
2/11/2013 | Microcurrent Stimulation to Treat Macular Degeneration | |||||
| Sanofi | SAR422459 | Drug | Interventional | Stargardt's Disease |
NCT01367444 | Phase 1/Phase 2 | Terminated |
5/19/2020 | Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration | Results | |
| University of Michigan | Observational | Stargardt Disease |
NCT01676766 | Terminated |
11/4/2016 | Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease | Trans Am Ophthalmol Soc-2008, Retina-2009, Arch Ophthalmol-2008, Exp Eye Res-2010 |